Company Overview
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, analytical, and other services. It also supplies specific pathogen free lab animals; breeders and distributes rodent models; and designs and develops of syngeneic / xenograft models for evaluation of anti-cancer agents evaluation, as well as offers custom rodent models, stem cell products, and lab animal diets. In addition, the company provides regulatory and non-regulatory IND preclinical development services; and screening and evaluating molecules for various pharmacological properties. The company was formerly known as Sunshine Factors & Exports Limited and changed its name to Vivo Bio Tech Limited in September 2002. Vivo Bio Tech Limited was incorporated in 1987 and is based in Hyderabad, India.
Recent Developments
- Mar 2026 Revenue of ₹53.33 Cr (+14.3% YoY); net profit ₹-1.71 Cr.
- Trailing 12 Months Year-on-year growth — revenue +14.1%, earnings -89.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.7%, profit CAGR -54.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.70% |
| 1 Year: | 14.10% |
Compounded Profit Growth
| 5 Years: | -54.83% |
| 1 Year: | -89.20% |
Stock Price Performance
| 1 Year: | -23.04% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -12.03% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)44.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -54.8% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VIVOBIOT Vivo Bio Tech Limited NSEPHARMA | 14.70 | -9.93 | ₹32.62 Cr | 0.00% | 7.19% | -1.83% | 0.70% | -54.83% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,758.00 | 34.88 | ₹4.22 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,162.00 | 83.32 | ₹2.43 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,615.30 | 73.73 | ₹1.76 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,135.00 | 25.30 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 634.25 | 165.17 | ₹1.10 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,604.50 | 52.35 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,002.50 | 98.99 | ₹1.08 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,330.90 | 31.92 | ₹1.08 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 12.51 Cr | 13.11 Cr | 13.51 Cr | 14.20 Cr | 14.28 Cr |
| Cost of Revenue | - | 1.51 Cr | 2.09 Cr | 2.16 Cr | 2.37 Cr | 1.86 Cr |
| Gross Profit | - | 11.01 Cr | 11.01 Cr | 11.35 Cr | 11.83 Cr | 12.42 Cr |
| Operating Expenses | - | 8.16 Cr | 8.17 Cr | 8.52 Cr | 9.53 Cr | 10.90 Cr |
| Operating Income | - | 2.85 Cr | 2.84 Cr | 2.83 Cr | 2.30 Cr | 1.52 Cr |
| EBITDA | - | 5.63 Cr | 5.55 Cr | 5.63 Cr | 4.48 Cr | 5.11 Cr |
| Interest Expense | - | 1.50 Cr | 1.47 Cr | 1.40 Cr | 1.48 Cr | 1.24 Cr |
| Pretax Income | - | 1.48 Cr | 1.51 Cr | 1.57 Cr | 25.11 L | 33.86 L |
| Tax Provision | - | 14.29 L | 64.05 L | 32.16 L | 5.41 Cr | 15.10 L |
| Net Income | - | 1.34 Cr | 86.86 L | 1.25 Cr | -5.16 Cr | 18.76 L |
| Diluted EPS | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 52.23 Cr | 45.45 Cr | 46.67 Cr | 53.33 Cr |
| Cost of Revenue | - | 6.77 Cr | 3.85 Cr | 5.79 Cr | 8.13 Cr |
| Gross Profit | - | 45.46 Cr | 41.60 Cr | 40.88 Cr | 45.21 Cr |
| Operating Expenses | - | 32.89 Cr | 29.61 Cr | 29.39 Cr | 34.39 Cr |
| Operating Income | - | 12.57 Cr | 11.99 Cr | 11.49 Cr | 10.82 Cr |
| EBITDA | - | 21.54 Cr | 21.13 Cr | 25.31 Cr | 21.34 Cr |
| Interest Expense | - | 7.65 Cr | 7.78 Cr | 7.50 Cr | 5.85 Cr |
| Pretax Income | - | 4.62 Cr | 4.06 Cr | 8.79 Cr | 4.81 Cr |
| Tax Provision | - | 1.97 Cr | 1.53 Cr | 1.51 Cr | 6.52 Cr |
| Net Income | - | 2.65 Cr | 2.53 Cr | 7.28 Cr | -1.71 Cr |
| Diluted EPS | - | 1.78 | 1.51 | 4.76 | -0.82 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 123.03 Cr | 137.13 Cr | 143.23 Cr | 178.43 Cr |
| Current Assets | - | 31.79 Cr | 47.23 Cr | 41.94 Cr | 28.42 Cr |
| Cash & Equivalents | - | 1.37 Cr | 1.39 Cr | 1.28 Cr | 1.44 Cr |
| Inventory | - | 7.97 Cr | 8.77 Cr | 7.79 Cr | 8.15 Cr |
| Receivables | - | 12.38 Cr | 11.79 Cr | 11.25 Cr | 11.75 Cr |
| Total Liabilities | - | 71.16 Cr | 82.73 Cr | 65.33 Cr | 85.27 Cr |
| Current Liabilities | - | 24.97 Cr | 37.91 Cr | 27.84 Cr | 30.23 Cr |
| Long Term Debt | - | 43.09 Cr | 41.79 Cr | 34.94 Cr | 46.61 Cr |
| Total Debt | - | 62.40 Cr | 73.06 Cr | 54.02 Cr | 67.38 Cr |
| Total Equity | - | 51.87 Cr | 54.40 Cr | 77.90 Cr | 93.16 Cr |
| Shares Outstanding | - | 1.49 Cr | 1.49 Cr | 1.72 Cr | 2.22 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 14.83 Cr | 15.52 Cr | 11.83 Cr | 34.93 Cr |
| Investing Cash Flow | - | -4.00 Cr | -7.95 Cr | -15.84 Cr | -59.35 Cr |
| Financing Cash Flow | - | -11.18 Cr | -7.56 Cr | 3.90 Cr | 24.57 Cr |
| Capital Expenditure | - | -4.00 Cr | -7.95 Cr | -22.27 Cr | -37.44 Cr |
| Free Cash Flow | - | 10.84 Cr | 7.57 Cr | -10.44 Cr | -2.51 Cr |
| Net Change in Cash | - | -33.88 L | 1.49 L | -10.90 L | 15.49 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 87.0% | 91.5% | 87.6% | 84.8% |
| Operating Margin % | - | 24.1% | 26.4% | 24.6% | 20.3% |
| Net Margin % | - | 5.1% | 5.6% | 15.6% | -3.2% |
| ROE % | - | 5.1% | 4.6% | 9.3% | -1.8% |
| ROCE % | - | 12.8% | 12.1% | 10.0% | 7.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VIVOBIOT
Vivo Bio Tech Limited (VIVOBIOT.BO) Analyst Insights, Price Targets & Recommendations - Yahoo Finance - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTFAxX3NydGQ3ODBobjVaWGNoaHhmMkV1U0ZHSkk1ZjlSQV9XdXdyYW9Ucm9OMnVYWXMzOTY2TTBPQlhXaXVZYUJFXzFtUjg4dG9KRng4U2NKcWJySmx0eTF2anN2dENHWXlQWndOZmtzVVZ6Zw?oc=5" target="_blank">Vivo Bio Tech…
Vivo Bio Tech Limited (VIVOBIOT.BO) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE9mVGZ6RkpOQzBCd3NsR1hKSkhXRDhDXzhSTXBpaFdVSnM3WHhGTmZKZG5jalRhWFhJSGFsNjAybEtvdlBkcDVvekV6MXdkd0Vnb1RQNVZJMXlESGZHYnB0U3FCMXVKSVNJS2djeTFxQzZWUQ?oc=5" target="_blank">Vivo Bio Tech…
VIVOBIOT Stock Price and Chart — NSE:VIVOBIOT - TradingView
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE5rcXVNeGQyOWRFZnVhblB5LU44eGhiUG1haWM3LWNTamNkanZMVndXdDNQSXFsUldTMzJZUXdiLW5FcjcxWTN1a1Q0dGlSM1YxRjhQMDBHdFZOS2tGMFE?oc=5" target="_blank">VIVOBIOT Stock Price and Chart — NSE:VIV…
Dwight Technologies Private Limited acquired an additional 5.41% stake in Vivo Bio Tech Limited. - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPN3h0SmFDX2p4WFRQZFBuSERuZU1WaC1MdlNsTGpPLTRwVlpXbXlnU2gwUXlUeEZvdTh6U21WUnB2aWpMYmJtdDI0OEkyUEpBZ1VCMHJMT2VVTHBfZ051VC1RYTVpZEppTXFMUGd1OVpLaDhBV3RhZU1RTkdCUVkyMF9vNVNoc29QQ1kzOT…
VIVOBIOT Share Price Today - Vivo Bio Tech on NSE/BSE - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTFA2Y0V5YlM4bE1zMjhzRVdoYi1sa05PVng5NmJHXzE0eWRscEdsVnVyZTVDRU8tMEJDUVlpUW1KTVR2dDF2OTZNNllZNlVYb1FDLXU1NEtWM0k?oc=5" target="_blank">VIVOBIOT Share Price Today - Vivo Bio Tech on NS…
APL Stock Price and Chart — BSE:APL - TradingView
<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTFBxUV9GNl9vMVpmakJWQjlpUU9TUkFhWnI4ZWw0QVRCZ0dnUXh0WWRwd1hMMFVfUndqMDNGNXJNUWxNUVBMQ0h4ZkEzY3FuZVdWQXZvLXJTaw?oc=5" target="_blank">APL Stock Price and Chart — BSE:APL</a> &nbs…
VIVOBIOT — Frequently Asked Questions
What is the current share price of Vivo Bio Tech Limited (VIVOBIOT)?
As of 2026-10-24 04:55 IST, Vivo Bio Tech Limited (VIVOBIOT) trades at ₹14.70 on NSE. Its 52-week range is ₹13.63 to ₹19.29.
What is the market capitalisation of VIVOBIOT?
Vivo Bio Tech Limited (VIVOBIOT) has a market capitalisation of ₹32.62 Cr on NSE.
What is the P/E ratio of VIVOBIOT?
VIVOBIOT trades at a trailing price-to-earnings (P/E) ratio of -9.93. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 0.37.
What is the return on equity (ROE) of VIVOBIOT?
VIVOBIOT has a return on equity (ROE) of -1.83%. Its return on capital employed (ROCE) is 7.19%.
Is VIVOBIOT a good stock to buy?
This page provides a data-driven analysis of Vivo Bio Tech Limited (VIVOBIOT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.